Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;66(3):317-323.
doi: 10.1007/s00234-023-03279-7. Epub 2024 Jan 6.

Low rCBV values in glioblastoma tumor progression under chemoradiotherapy

A Hilario  1 , E Salvador  2 , A Cardenas  2 , J Romero  2 , C Lechuga  2 , Z Chen  2 , A Martinez de Aragon  2 , A Perez-Nuñez  3 , A Hernandez-Lain  4 , J Sepulveda  5 , A Lagares  3 , O Toldos  4 , V Rodriguez-Gonzalez  6 , A Ramos  2
Affiliations

Low rCBV values in glioblastoma tumor progression under chemoradiotherapy

A Hilario et al. Neuroradiology. 2024 Mar.

Abstract

Purpose: After standard treatment for glioblastoma, perfusion MRI remains challenging for differentiating tumor progression from post-treatment changes. Our objectives were (1) to correlate rCBV values at diagnosis and at first tumor progression and (2) to analyze the relationship of rCBV values at tumor recurrence with enhancing volume, localization of tumor progression, and time elapsed since the end of radiotherapy in tumor recurrence.

Methods: Inclusion criteria were (1) age > 18 years, (2) histologically confirmed glioblastoma treated with STUPP regimen, and (3) tumor progression according to RANO criteria > 12 weeks after radiotherapy. Co-registration of segmented enhancing tumor VOIs with dynamic susceptibility contrast perfusion MRI was performed using Olea Sphere software. For tumor recurrence, we correlated rCBV values with enhancing tumor volume, with recurrence localization, and with time elapsed from the end of radiotherapy to progression. Analyses were performed with SPSS software.

Results: Sixty-four patients with glioblastoma were included in the study. Changes in rCBV values between diagnosis and first tumor progression were significant (p < 0.001), with a mean and median decreases of 32% and 46%, respectively. Mean rCBV values were also different (p < 0.01) when tumors progressed distally (radiation field rCBV values of 1.679 versus 3.409 distally). However, changes and, therefore, low rCBV values after radiotherapy in tumor recurrence were independent of time.

Conclusion: Chemoradiation alters tumor perfusion and rCBV values may be decreased in the setting of tumor progression. Changes in rCBV values with respect to diagnosis, with low rCBV in tumor progression, are independent of time but related to the site of recurrence.

Keywords: Cerebral blood volume; Dynamic susceptibility contrast perfusion MRI; Glioblastoma; Post-treatment changes; Tumor progression; rCBV.

PubMed Disclaimer

References

    1. Shukla G, Alexander GS, Bakas S et al (2017) Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol 6(4):40. https://doi.org/10.21037/cco.2017.06.28
    1. Abdulla S, Saada J, Johnson G et al (2015) Tumor progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. Clin Radiol 70(11):1299–1312. https://doi.org/10.1016/j.crad.2015.06.096 - DOI - PubMed
    1. Weller M, van den Bent PM et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186. https://doi.org/10.1038/s41571-020-00447-z - DOI - PubMed
    1. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. https://doi.org/10.1200/JCO.2009.26.354 - DOI - PubMed
    1. Zikou A, Sioka C, Alexiou G et al (2018) Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging. https://doi.org/10.1155/2018/6828396 - DOI - PubMed - PMC

LinkOut - more resources